References:
  1. OPTN/SRTR 2018 annual data report: Introduction. Am J Transplant. 2020;20 Suppl s1(s1):11–9.
  2. Brull SJ, Naguib M. Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex. Drug Des Devel Ther. 2009;3:119–29
  3. Hristovska A-M, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8:CD012763.
  4. De Kam P-J, Grobara P, Prohn M, Höppener F, Kluft C, Burggraaf J, et al. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. Int J Clin Pharmacol Ther. 2014;52(3):227–36.
  5. Mueller A, Platz K, Kremer B. Early postoperative complications following liver transplantation. Best Pract Res Clin Gastroenterol. 2004;18(5):881–900.
  6. Taner CB, Willingham DL, Bulatao IG, Shine TS, Peiris P, Torp KD, et al. Is a mandatory intensive care unit stay needed after liver transplantation? Feasibility of fast-tracking to the surgical ward after liver transplantation. Liver Transpl. 2012;18(3):361–9.
  7. Everson GT. A hepatologist’s perspective on the management of coagulation disorders before liver tranplantation. Liver Transpl Surg. 1997;3(6):646–52.
  8. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol. 2010;148(4):507–21.
  9. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56.
  10. Rahe-Meyer N, Fennema H, Schulman S, Klimscha W, Przemeck M, Blobner M, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology. 2014;121(5):969–77.
  11. Summary of product characteristics, Bridion. 2015. Fda.gov. [cited 2021 Jan 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf
  12. Dirkmann D, Britten MW, Pauling H, Weidle J, Volbracht L, Görlinger K, et al. Anticoagulant effect of Sugammadex: Just an in vitro artifact. Anesthesiology. 2016;124(6):1277–85.
  13. De Kam P-J, El Galta R, Kruithof AC, Fennema H, van Lierop M-J, Mihara K, et al. No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters. Int J Clin Pharmacol Ther. 2013;51(12):976–85.
  14. De Kam P-J, Kruithof AC, van Lierop M-J, Moerland M, Dennie J, Troyer MD, et al. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects. Int J Clin Pharmacol Ther. 2014;52(8):631–41.
  15. Taş N, Korkmaz H, Yağan Ö, Korkmaz M. Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: A randomized prospective study. Med Sci Monit. 2015;21:2382–6.
  16. Raft J, Betala Belinga JF, G J, Desandes E, Longrois D, Meistelman C. Clinical evaluation of post-surgical bleeding after a sugammadex injection. Ann Fr Anesth Reanim 2011; 30:714
  17. Moon Y-J, Kim S-H, Kim J-W, Lee Y-K, Jun I-G, Hwang G-S. Comparison of postoperative coagulation profiles and outcome for sugammadex versus pyridostigmine in 992 living donors after living-donor hepatectomy. Medicine (Baltimore). 2018;97(11):e0129.
  18. Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol. 2017;15(4):584-593.e2.
  19. Rezonja K, Sostaric M, Vidmar G, Mars T. Dexamethasone produces dose-dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle cells. Anesth Analg. 2014;118(4):755–63.
  20. Rezonja K, Mars T, Jerin A, Kozelj G, Pozar-Lukanovic N, Sostaric M. Dexamethasone does not diminish sugammadex reversal of neuromuscular block - clinical study in surgical patients undergoing general anesthesia. BMC Anesthesiol. 2016;16(1):101
  21. Arslantas R, Cevik BE. Retrospective investigation of grafted kidney function after reversal of neuromuscular blockade using neostigmine or sugammadex. Transplant Proc. 2019;51(7):2265–7.
  22. Deljou A, Schroeder DR, Ballinger BA, Sprung J, Weingarten TN. Effects of sugammadex on time of first postoperative bowel movement: A retrospective analysis. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):294–301.